New Two-Pronged drug challenges standard chemo in fight against tough bile duct cancers
NCT ID NCT06529718
Summary
This study is testing whether a new drug called ivonescimab works better than standard chemotherapy for people with advanced bile duct cancer whose first treatment has stopped working. It will involve 72 patients who previously took part in a related screening study. Participants will be randomly assigned to receive either the new drug or the standard chemotherapy regimen to see which one better controls the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Eugène Marquis
RECRUITINGRennes, France
Contact
Contact
-
Institute Mutualiste Montsouris
NOT_YET_RECRUITINGParis, France
Contact
Contact
-
University College London
NOT_YET_RECRUITINGLondon, United Kingdom
Contact
Contact
Conditions
Explore the condition pages connected to this study.